WO2005096784A2 - Benzotriazine inhibitors of kinases - Google Patents
Benzotriazine inhibitors of kinases Download PDFInfo
- Publication number
- WO2005096784A2 WO2005096784A2 PCT/US2005/012057 US2005012057W WO2005096784A2 WO 2005096784 A2 WO2005096784 A2 WO 2005096784A2 US 2005012057 W US2005012057 W US 2005012057W WO 2005096784 A2 WO2005096784 A2 WO 2005096784A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- mmol
- subject
- disorder
- methyl
- Prior art date
Links
- 0 *N1CCN(CCBr)CC1 Chemical compound *N1CCN(CCBr)CC1 0.000 description 13
- HUKKIICEYSQETK-UHFFFAOYSA-N Cc1cc(-c2cc(Cl)ccc2OC)cc2c1nc(Nc(cc1)ccc1OCCN1CCCC1)nn2 Chemical compound Cc1cc(-c2cc(Cl)ccc2OC)cc2c1nc(Nc(cc1)ccc1OCCN1CCCC1)nn2 HUKKIICEYSQETK-UHFFFAOYSA-N 0.000 description 2
- VAWLAPYBUJTXRS-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc(cc1)ccc1S(C1CCNCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc(cc1)ccc1S(C1CCNCC1)(=O)=O)nn2 VAWLAPYBUJTXRS-UHFFFAOYSA-N 0.000 description 2
- BOQLSYBMPFBUNE-UHFFFAOYSA-N Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc1nc(C(NCCN3CCCC3)=O)c[s]1)nn2 Chemical compound Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc1nc(C(NCCN3CCCC3)=O)c[s]1)nn2 BOQLSYBMPFBUNE-UHFFFAOYSA-N 0.000 description 2
- MVFMLKKYUBDPJB-ZRDIBKRKSA-N C/C(/Nc1nc(c(C)cc(-c2cc(O)ccc2Cl)c2)c2nn1)=C\N=C(/C)\NC(C)=O Chemical compound C/C(/Nc1nc(c(C)cc(-c2cc(O)ccc2Cl)c2)c2nn1)=C\N=C(/C)\NC(C)=O MVFMLKKYUBDPJB-ZRDIBKRKSA-N 0.000 description 1
- KDTFQAJYJIGSFS-UHFFFAOYSA-N CC(C)N(CCN1CCCC1)S(c(cc1)ccc1Nc1nc(c(C)cc(-c2cc(O)ccc2Cl)c2)c2nn1)(=O)=O Chemical compound CC(C)N(CCN1CCCC1)S(c(cc1)ccc1Nc1nc(c(C)cc(-c2cc(O)ccc2Cl)c2)c2nn1)(=O)=O KDTFQAJYJIGSFS-UHFFFAOYSA-N 0.000 description 1
- RPSBJRWUMIHPGU-UHFFFAOYSA-N CC(C1(C)N=C(N)N=NC1=C1)C=C1Br Chemical compound CC(C1(C)N=C(N)N=NC1=C1)C=C1Br RPSBJRWUMIHPGU-UHFFFAOYSA-N 0.000 description 1
- VLWSURYZZHVLKO-UHFFFAOYSA-N CC(Nc(nc1)ccc1Nc(nnc1c2)nc1c(C)cc2-c(cc(cc1)O)c1Cl)=O Chemical compound CC(Nc(nc1)ccc1Nc(nnc1c2)nc1c(C)cc2-c(cc(cc1)O)c1Cl)=O VLWSURYZZHVLKO-UHFFFAOYSA-N 0.000 description 1
- BCAHGWFHBBMPHP-UHFFFAOYSA-N CC(Nc1cc(-c2c(C)cccc2C)cc2c1nc(Nc(cc1)ccc1OCCN1CCCC1)nn2)=O Chemical compound CC(Nc1cc(-c2c(C)cccc2C)cc2c1nc(Nc(cc1)ccc1OCCN1CCCC1)nn2)=O BCAHGWFHBBMPHP-UHFFFAOYSA-N 0.000 description 1
- XAOYXVXFTLCFFS-UHFFFAOYSA-N CC(Nc1cc(-c2c(C)cccc2C)cc2c1nc(Nc(cc1)ccc1S(N(CCN1CCCC1)C(C)=O)(=O)=O)nn2)=O Chemical compound CC(Nc1cc(-c2c(C)cccc2C)cc2c1nc(Nc(cc1)ccc1S(N(CCN1CCCC1)C(C)=O)(=O)=O)nn2)=O XAOYXVXFTLCFFS-UHFFFAOYSA-N 0.000 description 1
- KGYCQGOAGCBPEB-UHFFFAOYSA-N CC(Nc1cc(-c2c(C)cccc2C)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2)=O Chemical compound CC(Nc1cc(-c2c(C)cccc2C)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2)=O KGYCQGOAGCBPEB-UHFFFAOYSA-N 0.000 description 1
- PFVCCMOOCGLRPV-ZBEWQZTPSA-O CC1(C)OB(/C(/C=[NH2+])=C/N)OC1(C)C Chemical compound CC1(C)OB(/C(/C=[NH2+])=C/N)OC1(C)C PFVCCMOOCGLRPV-ZBEWQZTPSA-O 0.000 description 1
- QRQCJOYHTJFZNZ-UHFFFAOYSA-N CC1C=C(C)C(c(cc2[N+]([O-])=O)cc([NH+]([N-]3)[O-])c2N=C3Nc(cc2)ccc2OCCN2CCCC2)=C(C)C1 Chemical compound CC1C=C(C)C(c(cc2[N+]([O-])=O)cc([NH+]([N-]3)[O-])c2N=C3Nc(cc2)ccc2OCCN2CCCC2)=C(C)C1 QRQCJOYHTJFZNZ-UHFFFAOYSA-N 0.000 description 1
- KJIBUWZGIDVJIY-UHFFFAOYSA-N CCCCc(cc1)ccc1Nc1nc(c(C)cc(-c2c(C)cccc2C)c2)c2nn1 Chemical compound CCCCc(cc1)ccc1Nc1nc(c(C)cc(-c2c(C)cccc2C)c2)c2nn1 KJIBUWZGIDVJIY-UHFFFAOYSA-N 0.000 description 1
- CNHISCQPKKGDPO-UHFFFAOYSA-N CCOC(c1c[s]c(Br)n1)=O Chemical compound CCOC(c1c[s]c(Br)n1)=O CNHISCQPKKGDPO-UHFFFAOYSA-N 0.000 description 1
- YVVBCSYTBZHHQG-UHFFFAOYSA-N CCOc(cc1)ccc1Nc1nc(c(C)cc(-c2cc(OC)cc(OC)c2)c2)c2nn1 Chemical compound CCOc(cc1)ccc1Nc1nc(c(C)cc(-c2cc(OC)cc(OC)c2)c2)c2nn1 YVVBCSYTBZHHQG-UHFFFAOYSA-N 0.000 description 1
- LXIIGQZZJVXONE-UHFFFAOYSA-N CCOc1cc2nc(N)nnc2cc1-c1ccccc1C Chemical compound CCOc1cc2nc(N)nnc2cc1-c1ccccc1C LXIIGQZZJVXONE-UHFFFAOYSA-N 0.000 description 1
- ITLNVPRPOQCABR-UHFFFAOYSA-N Cc(c(-c(c(C)c1)cc2c1nc(Nc(cc1)ccc1C(N1CCN(C)CC1)=O)nn2)c1)ccc1Cl Chemical compound Cc(c(-c(c(C)c1)cc2c1nc(Nc(cc1)ccc1C(N1CCN(C)CC1)=O)nn2)c1)ccc1Cl ITLNVPRPOQCABR-UHFFFAOYSA-N 0.000 description 1
- PWKWAGIBTGYEHC-UHFFFAOYSA-N Cc(c(-c(c(C)c1)cc2c1nc(Nc(cc1)ccc1OCCN1CCCC1)nn2)c1)ccc1F Chemical compound Cc(c(-c(c(C)c1)cc2c1nc(Nc(cc1)ccc1OCCN1CCCC1)nn2)c1)ccc1F PWKWAGIBTGYEHC-UHFFFAOYSA-N 0.000 description 1
- PHSGAESTNBYAHM-UHFFFAOYSA-N Cc(c(-c1cc(C)c2nc(Nc(cc3)ccc3S(NCCN3CCCC3)(=O)=O)nnc2c1)c1)ccc1O Chemical compound Cc(c(-c1cc(C)c2nc(Nc(cc3)ccc3S(NCCN3CCCC3)(=O)=O)nnc2c1)c1)ccc1O PHSGAESTNBYAHM-UHFFFAOYSA-N 0.000 description 1
- QPQTXSMCSCYFGQ-UHFFFAOYSA-N Cc(c(-c1cc(CO)ccc1)c1)cc2c1nnc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)n2 Chemical compound Cc(c(-c1cc(CO)ccc1)c1)cc2c1nnc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)n2 QPQTXSMCSCYFGQ-UHFFFAOYSA-N 0.000 description 1
- OUHRROUUMISCGY-UHFFFAOYSA-N Cc(c(-c1cc(O)ccc1)c1)cc2c1nnc(Nc(cc1)ccc1OCCN1CCCC1)n2 Chemical compound Cc(c(-c1cc(O)ccc1)c1)cc2c1nnc(Nc(cc1)ccc1OCCN1CCCC1)n2 OUHRROUUMISCGY-UHFFFAOYSA-N 0.000 description 1
- CPKWNMKGJMCCPZ-UHFFFAOYSA-N Cc(c(-c1cc(O)ccc1Cl)c1)cc2c1nnc(Nc(cc1)ccc1C(N1CCN(C)CC1)=O)n2 Chemical compound Cc(c(-c1cc(O)ccc1Cl)c1)cc2c1nnc(Nc(cc1)ccc1C(N1CCN(C)CC1)=O)n2 CPKWNMKGJMCCPZ-UHFFFAOYSA-N 0.000 description 1
- MVVFDSPVLRMEIA-UHFFFAOYSA-N Cc(c(-c1cc2nnc(Nc(cc3)ccc3OCCN3CCCC3)nc2cc1C)c1)ccc1O Chemical compound Cc(c(-c1cc2nnc(Nc(cc3)ccc3OCCN3CCCC3)nc2cc1C)c1)ccc1O MVVFDSPVLRMEIA-UHFFFAOYSA-N 0.000 description 1
- BPKCVPQTTDYEFX-UHFFFAOYSA-N Cc(c(Br)c1)cc2c1nnc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)n2 Chemical compound Cc(c(Br)c1)cc2c1nnc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)n2 BPKCVPQTTDYEFX-UHFFFAOYSA-N 0.000 description 1
- QOZSLSADUPZZKW-UHFFFAOYSA-N Cc(c(C)c1)ccc1Nc1nc(c(C)cc(-c2cc(OC)cc(OC)c2)c2)c2nn1 Chemical compound Cc(c(C)c1)ccc1Nc1nc(c(C)cc(-c2cc(OC)cc(OC)c2)c2)c2nn1 QOZSLSADUPZZKW-UHFFFAOYSA-N 0.000 description 1
- HUBLIJJKLJKNJL-UHFFFAOYSA-N Cc(cc1)ccc1Nc1nc(c(C)cc(-c2c(C)cccc2C)c2)c2nn1 Chemical compound Cc(cc1)ccc1Nc1nc(c(C)cc(-c2c(C)cccc2C)c2)c2nn1 HUBLIJJKLJKNJL-UHFFFAOYSA-N 0.000 description 1
- KDWPMSHIURZDIJ-UHFFFAOYSA-N Cc(cccc1C)c1-c(cc1C)cc2c1nc(Nc(cccc1)c1OC)nn2 Chemical compound Cc(cccc1C)c1-c(cc1C)cc2c1nc(Nc(cccc1)c1OC)nn2 KDWPMSHIURZDIJ-UHFFFAOYSA-N 0.000 description 1
- NGYGJKWFCRECQN-UHFFFAOYSA-N Cc1c2nc(Nc(cc3)ccc3S(N3CCN(C)CC3)(=O)=O)nnc2cc(-c2cc(O)ccc2Cl)c1 Chemical compound Cc1c2nc(Nc(cc3)ccc3S(N3CCN(C)CC3)(=O)=O)nnc2cc(-c2cc(O)ccc2Cl)c1 NGYGJKWFCRECQN-UHFFFAOYSA-N 0.000 description 1
- OLAQXRSNCGXDSZ-UHFFFAOYSA-N Cc1c2nc(Nc(cc3)cnc3OC)nnc2cc(-c2cc(O)ccc2Cl)c1 Chemical compound Cc1c2nc(Nc(cc3)cnc3OC)nnc2cc(-c2cc(O)ccc2Cl)c1 OLAQXRSNCGXDSZ-UHFFFAOYSA-N 0.000 description 1
- NZKIVHPJIICWNI-UHFFFAOYSA-N Cc1c2nc(Nc3cccc(S(N4CCN(C)CC4)(=O)=O)c3)nnc2cc(-c2cc(OC)ccc2Cl)c1 Chemical compound Cc1c2nc(Nc3cccc(S(N4CCN(C)CC4)(=O)=O)c3)nnc2cc(-c2cc(OC)ccc2Cl)c1 NZKIVHPJIICWNI-UHFFFAOYSA-N 0.000 description 1
- IKBJFCQBZQVKJN-UHFFFAOYSA-N Cc1c2nc(Nc3cccc(SCCN4CCCC4)c3)nnc2cc(-c2cc(OC)ccc2Cl)c1 Chemical compound Cc1c2nc(Nc3cccc(SCCN4CCCC4)c3)nnc2cc(-c2cc(OC)ccc2Cl)c1 IKBJFCQBZQVKJN-UHFFFAOYSA-N 0.000 description 1
- TUMITOMFWDJDDQ-UHFFFAOYSA-N Cc1cc(-c(c(Cl)ccc2)c2Cl)cc2c1nc(Nc(cc1)ccc1S(N(C)CCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c(c(Cl)ccc2)c2Cl)cc2c1nc(Nc(cc1)ccc1S(N(C)CCN1CCCC1)(=O)=O)nn2 TUMITOMFWDJDDQ-UHFFFAOYSA-N 0.000 description 1
- ODSUGJKWJKAXHT-UHFFFAOYSA-N Cc1cc(-c(c(Cl)ccc2)c2Cl)cc2c1nc(Nc1ccncc1)nn2 Chemical compound Cc1cc(-c(c(Cl)ccc2)c2Cl)cc2c1nc(Nc1ccncc1)nn2 ODSUGJKWJKAXHT-UHFFFAOYSA-N 0.000 description 1
- WQACVRFKZIYHIM-UHFFFAOYSA-N Cc1cc(-c(c(Cl)ccc2)c2O)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c(c(Cl)ccc2)c2O)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 WQACVRFKZIYHIM-UHFFFAOYSA-N 0.000 description 1
- RVVMRHQNWBCVAS-UHFFFAOYSA-N Cc1cc(-c(c(Cl)ccc2OC)c2F)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c(c(Cl)ccc2OC)c2F)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 RVVMRHQNWBCVAS-UHFFFAOYSA-N 0.000 description 1
- WGOCYFJXNFKHER-UHFFFAOYSA-N Cc1cc(-c(cc(cc2)O)c2Cl)cc2c1nc(N)nn2 Chemical compound Cc1cc(-c(cc(cc2)O)c2Cl)cc2c1nc(N)nn2 WGOCYFJXNFKHER-UHFFFAOYSA-N 0.000 description 1
- VTSREOCPHUZXLM-UHFFFAOYSA-N Cc1cc(-c2cc(NS(C)(=O)=O)ccc2)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c2cc(NS(C)(=O)=O)ccc2)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 VTSREOCPHUZXLM-UHFFFAOYSA-N 0.000 description 1
- PFAJPANEBVTDTK-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(NCCCCN1CCCC1)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(NCCCCN1CCCC1)nn2 PFAJPANEBVTDTK-UHFFFAOYSA-N 0.000 description 1
- NMSHJWKGPWRUSI-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc(cc1)ccc1C(N(CC1)CCS1(=O)=O)=O)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc(cc1)ccc1C(N(CC1)CCS1(=O)=O)=O)nn2 NMSHJWKGPWRUSI-UHFFFAOYSA-N 0.000 description 1
- NXTAONONNMIHOO-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc(cc1)ccc1S(N(C)CCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc(cc1)ccc1S(N(C)CCN1CCCC1)(=O)=O)nn2 NXTAONONNMIHOO-UHFFFAOYSA-N 0.000 description 1
- MZDZFBRVVPRKIT-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc1cc(N(C)C)ccc1)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc1cc(N(C)C)ccc1)nn2 MZDZFBRVVPRKIT-UHFFFAOYSA-N 0.000 description 1
- RIBZJJDUKXDJMG-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc1cccc(OCCN3CCCC3)c1)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc1cccc(OCCN3CCCC3)c1)nn2 RIBZJJDUKXDJMG-UHFFFAOYSA-N 0.000 description 1
- NYABGVVHNWYTPF-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc1nc(C(NCCN3CCCC3)=O)c[s]1)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2c1nc(Nc1nc(C(NCCN3CCCC3)=O)c[s]1)nn2 NYABGVVHNWYTPF-UHFFFAOYSA-N 0.000 description 1
- GFXCTQSIXXAOBE-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3cccc(S(NCCN(C)C)(=O)=O)c3)nc12 Chemical compound Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3cccc(S(NCCN(C)C)(=O)=O)c3)nc12 GFXCTQSIXXAOBE-UHFFFAOYSA-N 0.000 description 1
- XWNOQCSTHKPRDW-UHFFFAOYSA-N Cc1cc(-c2cc(O)ccc2[ClH]C)cc2c1nc(NC(C=C1)=CN(C)C1C(NCCN1CCCC1)=O)nn2 Chemical compound Cc1cc(-c2cc(O)ccc2[ClH]C)cc2c1nc(NC(C=C1)=CN(C)C1C(NCCN1CCCC1)=O)nn2 XWNOQCSTHKPRDW-UHFFFAOYSA-N 0.000 description 1
- JFPQJONXEVRXFI-UHFFFAOYSA-N Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(N)nn2 Chemical compound Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(N)nn2 JFPQJONXEVRXFI-UHFFFAOYSA-N 0.000 description 1
- ODPQIVUHVCGRLP-UHFFFAOYSA-N Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1ccc(C(NCCN3CCCC3)=O)nc1)nn2 Chemical compound Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1ccc(C(NCCN3CCCC3)=O)nc1)nn2 ODPQIVUHVCGRLP-UHFFFAOYSA-N 0.000 description 1
- YEGWRBLGTMVLMJ-UHFFFAOYSA-N Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1cccc(OCCN3CCCC3)c1)nn2 Chemical compound Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1cccc(OCCN3CCCC3)c1)nn2 YEGWRBLGTMVLMJ-UHFFFAOYSA-N 0.000 description 1
- GPAGRRIIGMGNMD-UHFFFAOYSA-N Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1nc(C(NCCN3CCCC3)=O)c[s]1)nn2 Chemical compound Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1nc(C(NCCN3CCCC3)=O)c[s]1)nn2 GPAGRRIIGMGNMD-UHFFFAOYSA-N 0.000 description 1
- RTXLIJJDHXCIIF-UHFFFAOYSA-N Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1nc(C)nc(OCCN3CCCC3)c1)nn2 Chemical compound Cc1cc(-c2cc(OC)ccc2Cl)cc2c1nc(Nc1nc(C)nc(OCCN3CCCC3)c1)nn2 RTXLIJJDHXCIIF-UHFFFAOYSA-N 0.000 description 1
- PFHBGGIVIPCMIS-UHFFFAOYSA-N Cc1cc(-c2cccc(O)c2F)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1cc(-c2cccc(O)c2F)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 PFHBGGIVIPCMIS-UHFFFAOYSA-N 0.000 description 1
- RGCPQJWQLGCWGM-UHFFFAOYSA-N Cc1cc(Br)cc2c1nc(N)nn2 Chemical compound Cc1cc(Br)cc2c1nc(N)nn2 RGCPQJWQLGCWGM-UHFFFAOYSA-N 0.000 description 1
- BCJNHDIVYXFDMA-UHFFFAOYSA-N Cc1cc2nc(Nc(cc3)ccc3S(N(C)CCN3CCCC3)(=O)=O)nnc2cc1-c1cc(OC)ccc1Cl Chemical compound Cc1cc2nc(Nc(cc3)ccc3S(N(C)CCN3CCCC3)(=O)=O)nnc2cc1-c1cc(OC)ccc1Cl BCJNHDIVYXFDMA-UHFFFAOYSA-N 0.000 description 1
- HVKLKXJHEXZHRA-UHFFFAOYSA-N Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc(cc1)ccc1OCCCN1CCCC1)nn2 Chemical compound Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc(cc1)ccc1OCCCN1CCCC1)nn2 HVKLKXJHEXZHRA-UHFFFAOYSA-N 0.000 description 1
- PKACVUDGDZAACR-UHFFFAOYSA-N Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc(cc1Cl)ccc1Cl)nn2 Chemical compound Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc(cc1Cl)ccc1Cl)nn2 PKACVUDGDZAACR-UHFFFAOYSA-N 0.000 description 1
- KZCMQDWEVKEHLN-UHFFFAOYSA-N Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc1cccc(S(NCCN(C)C)(=O)=O)c1)nn2 Chemical compound Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc1cccc(S(NCCN(C)C)(=O)=O)c1)nn2 KZCMQDWEVKEHLN-UHFFFAOYSA-N 0.000 description 1
- ZJQVYURHZFRKLA-UHFFFAOYSA-N Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc1ccncc1)nn2 Chemical compound Cc1cccc(C)c1-c(cc1C)cc2c1nc(Nc1ccncc1)nn2 ZJQVYURHZFRKLA-UHFFFAOYSA-N 0.000 description 1
- DMDJUVDEWDKOOC-UHFFFAOYSA-N Cc1cccc(Cl)c1-c(cc1C)cc2c1nc(Nc1ccncc1)nn2 Chemical compound Cc1cccc(Cl)c1-c(cc1C)cc2c1nc(Nc1ccncc1)nn2 DMDJUVDEWDKOOC-UHFFFAOYSA-N 0.000 description 1
- MISJXJNFFYOIPX-UHFFFAOYSA-N Cc1ccccc1-c(c(OC)c1)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 Chemical compound Cc1ccccc1-c(c(OC)c1)cc2c1nc(Nc(cc1)ccc1S(NCCN1CCCC1)(=O)=O)nn2 MISJXJNFFYOIPX-UHFFFAOYSA-N 0.000 description 1
- RHGHRAGIGDLNSO-UHFFFAOYSA-N Cc1ccncc1-c(c(C)c1)cc2c1nc(Nc(cc1)ccc1C(N1CCN(C)CC1)=O)nn2 Chemical compound Cc1ccncc1-c(c(C)c1)cc2c1nc(Nc(cc1)ccc1C(N1CCN(C)CC1)=O)nn2 RHGHRAGIGDLNSO-UHFFFAOYSA-N 0.000 description 1
- BGVRDWFMIZTBBG-UHFFFAOYSA-N Cc1n[o]c(C)c1-c(cc1C)cc2c1nc(Nc(cc1)ccc1OC)nn2 Chemical compound Cc1n[o]c(C)c1-c(cc1C)cc2c1nc(Nc(cc1)ccc1OC)nn2 BGVRDWFMIZTBBG-UHFFFAOYSA-N 0.000 description 1
- RXBTXEBGONSTPB-UHFFFAOYSA-N Cc1n[o]c(C)c1-c(cc1C)cc2c1nc(Nc(cc1)ccc1OCCN1CCN(C)CC1)nn2 Chemical compound Cc1n[o]c(C)c1-c(cc1C)cc2c1nc(Nc(cc1)ccc1OCCN1CCN(C)CC1)nn2 RXBTXEBGONSTPB-UHFFFAOYSA-N 0.000 description 1
- CDCZPFYGOFSGLY-UHFFFAOYSA-N NC(C=C1)=CN(CCCN2CCCC2)C1=O Chemical compound NC(C=C1)=CN(CCCN2CCCC2)C1=O CDCZPFYGOFSGLY-UHFFFAOYSA-N 0.000 description 1
- WRXNJTBODVGDRY-UHFFFAOYSA-N NCCN1CCCC1 Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 1
- ROCVGJLXIARCAC-UHFFFAOYSA-N Nc(c(O)c1)ccc1O Chemical compound Nc(c(O)c1)ccc1O ROCVGJLXIARCAC-UHFFFAOYSA-N 0.000 description 1
- ZKLDPEWNXLYZLU-UHFFFAOYSA-N O=C(c1c[s]c(Br)n1)NCCN1CCCC1 Chemical compound O=C(c1c[s]c(Br)n1)NCCN1CCCC1 ZKLDPEWNXLYZLU-UHFFFAOYSA-N 0.000 description 1
- DIYRIYJMMLUTQP-UHFFFAOYSA-N O=S(c(cc1)ccc1Br)(NCCN1CCCC1)=O Chemical compound O=S(c(cc1)ccc1Br)(NCCN1CCCC1)=O DIYRIYJMMLUTQP-UHFFFAOYSA-N 0.000 description 1
- PJGOLCXVWIYXRQ-UHFFFAOYSA-N O=S(c1cc(Br)ccc1)(Cl)=O Chemical compound O=S(c1cc(Br)ccc1)(Cl)=O PJGOLCXVWIYXRQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005231507A AU2005231507B2 (en) | 2004-04-08 | 2005-04-07 | Benzotriazine inhibitors of kinases |
CN200580018660.1A CN101426772B (zh) | 2004-04-08 | 2005-04-07 | 激酶的苯并三嗪抑制物 |
EP05762774.7A EP1809614B1 (en) | 2004-04-08 | 2005-04-07 | Benzotriazine inhibitors of kinases |
CA2567574A CA2567574C (en) | 2004-04-08 | 2005-04-07 | Benzotriazine inhibitors of kinases |
NZ551027A NZ551027A (en) | 2004-04-08 | 2005-04-07 | Benzotriazine inhibitors of kinases |
IL178908A IL178908A (en) | 2004-04-08 | 2006-10-26 | Benzotriazines kinase inhibitors |
HK08100766.4A HK1110578A1 (en) | 2004-04-08 | 2008-01-21 | Benzotriazine inhibitors of kinases |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56123704P | 2004-04-08 | 2004-04-08 | |
US60/561,237 | 2004-04-08 | ||
US64343905P | 2005-01-12 | 2005-01-12 | |
US60/643,439 | 2005-01-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005096784A2 true WO2005096784A2 (en) | 2005-10-20 |
WO2005096784A3 WO2005096784A3 (en) | 2009-02-19 |
Family
ID=35125563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/012057 WO2005096784A2 (en) | 2004-04-08 | 2005-04-07 | Benzotriazine inhibitors of kinases |
Country Status (10)
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006131835A2 (en) * | 2005-02-01 | 2006-12-14 | Sentinel Oncology Limited | Heterocyclic triazines as hypoxic selective protein kinase inhibitors |
EP1799656A1 (en) * | 2004-08-25 | 2007-06-27 | Targegen, Inc. | Heterocyclic compounds and methods of use |
EP1893216A1 (en) * | 2005-06-08 | 2008-03-05 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
WO2010076238A1 (en) | 2008-12-29 | 2010-07-08 | Fovea Pharmaceuticals Sa | Substituted quinazoline compounds |
WO2010092041A1 (en) | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals Sa | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
US7858782B2 (en) | 2006-12-15 | 2010-12-28 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
WO2011161159A1 (en) | 2010-06-22 | 2011-12-29 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
JP2012528136A (ja) * | 2009-05-26 | 2012-11-12 | センティネル・オンコロジー・リミテッド | p70S6キナーゼの阻害剤としての置換ベンゾトリアジン類およびキノキサリン類 |
EP2543376A1 (en) * | 2004-04-08 | 2013-01-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
US8877924B2 (en) | 2009-06-09 | 2014-11-04 | NantBio Inc. | Benzyl substituted triazine derivatives and their therapeutical applications |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
AU2009322346B2 (en) * | 2008-12-03 | 2015-07-02 | The Scripps Research Institute | Stem cell cultures |
US9078902B2 (en) | 2009-06-09 | 2015-07-14 | Nantbioscience, Inc. | Triazine derivatives and their therapeutical applications |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9527816B2 (en) | 2005-05-10 | 2016-12-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10246393B2 (en) | 2016-10-31 | 2019-04-02 | Tosoh Corporation | Method for producing aromatic compound |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7208493B2 (en) * | 2002-10-03 | 2007-04-24 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
PT1951684T (pt) | 2005-11-01 | 2016-10-13 | Targegen Inc | Inibidores de cinases de tipo biaril-meta-pirimidina |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
RU2008127486A (ru) * | 2005-12-08 | 2010-01-20 | Милленниум Фармасьютикалз, Инк. (Us) | Бициклические соединения с ингибиторной активностью в отношении киназы |
US7691858B2 (en) * | 2006-04-25 | 2010-04-06 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
WO2009062112A2 (en) * | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as antimicrobials |
CA2723358A1 (en) * | 2008-05-05 | 2009-11-12 | Allison B. Reiss | Method for improving cardiovascular risk profile of cox inhibitors |
EP2447256A1 (en) * | 2010-10-21 | 2012-05-02 | Laboratorios Lesvi, S.L. | Process for obtaining dronedarone |
AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
WO2016089208A2 (en) | 2014-12-04 | 2016-06-09 | Stichting Maastricht Radiation Oncology "Maastro-Clinic" | Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents |
CN116410159B (zh) * | 2023-06-09 | 2023-08-22 | 济南国鼎医药科技有限公司 | 一种恩曲替尼中间体的制备方法及其应用 |
Family Cites Families (161)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2003199A (en) | 1930-05-31 | 1935-05-28 | Johnson Frank James | Automatic coal stoker |
US2003149A (en) | 1931-05-22 | 1935-05-28 | Autographic Register Co | Manifolding |
US2003065A (en) | 1931-06-20 | 1935-05-28 | John R Ditmars | Composition for coating sheets, fibrous stocks, and the like |
US2004102A (en) | 1932-02-24 | 1935-06-11 | Daniel A Dickey | Hollow steel propeller construction |
US2004138A (en) | 1932-11-30 | 1935-06-11 | Byers A M Co | Method of making wrought iron pipe |
US2002165A (en) | 1933-07-08 | 1935-05-21 | Charles A Winslow | Air cleaner |
US2003187A (en) | 1933-10-02 | 1935-05-28 | Frederick H Shaw | Automobile radio device |
US2003166A (en) | 1933-10-26 | 1935-05-28 | Zancan Ottavio | Front drive for motor cars |
US2001051A (en) | 1933-12-01 | 1935-05-14 | Angelina Mariani | Tamperproof meter box with cutout control and fuse drawer for electric meters |
US2004092A (en) | 1933-12-15 | 1935-06-11 | John L Chaney | Device for indicating the temperature of liquids |
US2003060A (en) | 1934-04-02 | 1935-05-28 | Ernest L Heckert | Thermostatic controlling device |
US2667486A (en) | 1951-05-24 | 1954-01-26 | Research Corp | 2,4-diamino pteridine and derivatives |
IL26578A (en) | 1965-10-04 | 1970-11-30 | Merck & Co Inc | Pethridine compounds and their preparation |
DE2255947A1 (de) | 1972-11-15 | 1974-05-22 | Bayer Ag | Substituierte 3-amino-benzo-1,2,4triazin-di-n-oxide (1,4), verfahren zu ihrer herstellung sowie ihre verwendung als antimikrobielle mittel |
IL44058A (en) | 1973-02-02 | 1978-10-31 | Ciba Geigy Ag | 3amino-1,2,4-benzotriazine 1,4-di-noxide derivatives, their preparation and compositions for the control of microorganisms containing them |
FR2275461A1 (fr) | 1974-06-18 | 1976-01-16 | Labaz | Nouveaux stabilisants des polymeres et copolymeres du chlorure de vinyle |
AU535258B2 (en) | 1979-08-31 | 1984-03-08 | Ici Australia Limited | Benzotriazines |
EP0059524A1 (en) | 1981-02-09 | 1982-09-08 | Smith and Nephew Associated Companies p.l.c. | Pharmaceutical composition containing aminopteridines or aminopyrimido(4,5-d)pyrimidines |
DE3205638A1 (de) | 1982-02-17 | 1983-08-25 | Hoechst Ag, 6230 Frankfurt | Trisubstituierte pyrimidin-5-carbonsaeuren und deren derivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
US4490289A (en) | 1982-09-16 | 1984-12-25 | Hoffmann-La Roche Inc. | Homogeneous human interleukin 2 |
US5624925A (en) | 1986-09-25 | 1997-04-29 | Sri International | 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents |
JP2598100B2 (ja) | 1988-08-31 | 1997-04-09 | キヤノン株式会社 | 電子写真感光体 |
US5214059A (en) | 1989-07-03 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Incorporated | 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders |
US5776502A (en) | 1989-07-18 | 1998-07-07 | Oncogene Science, Inc. | Methods of transcriptionally modulating gene expression |
US5665543A (en) | 1989-07-18 | 1997-09-09 | Oncogene Science, Inc. | Method of discovering chemicals capable of functioning as gene expression modulators |
JPH03127790A (ja) | 1989-10-11 | 1991-05-30 | Morishita Pharmaceut Co Ltd | N―(1h―テトラゾール―5―イル)―2―アニリノ―5―ピリミジンカルボキシアミド類及びその合成中間体 |
US5062685A (en) | 1989-10-11 | 1991-11-05 | Corning Incorporated | Coated optical fibers and cables and method |
GB9003553D0 (en) | 1990-02-16 | 1990-04-11 | Ici Plc | Herbicidal compositions |
JP2839106B2 (ja) | 1990-02-19 | 1998-12-16 | キヤノン株式会社 | 電子写真感光体 |
MY107955A (en) | 1990-07-27 | 1996-07-15 | Ici Plc | Fungicides. |
GB9016800D0 (en) | 1990-07-31 | 1990-09-12 | Shell Int Research | Tetrahydropyrimidine derivatives |
DE4025891A1 (de) | 1990-08-16 | 1992-02-20 | Bayer Ag | Pyrimidyl-substituierte acrylsaeureester |
JPH05345780A (ja) | 1991-12-24 | 1993-12-27 | Kumiai Chem Ind Co Ltd | ピリミジンまたはトリアジン誘導体及び除草剤 |
HUT63941A (en) | 1992-05-15 | 1993-11-29 | Hoechst Ag | Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same |
US5482951A (en) | 1992-05-29 | 1996-01-09 | Kumiai Chemical Industry Co., Ltd. | Triazole derivatives as well as insecticide and acaricide |
US5763441A (en) | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
JPH0741461A (ja) | 1993-05-27 | 1995-02-10 | Eisai Co Ltd | スルホン酸エステル誘導体 |
JPH0782183A (ja) | 1993-09-09 | 1995-03-28 | Canon Inc | 液晶中間体化合物、液晶性化合物、高分子液晶化合物、高分子液晶共重合体化合物、それらの組成物、液晶素子および記録装置 |
DE4338704A1 (de) | 1993-11-12 | 1995-05-18 | Hoechst Ag | Stabilisierte Oligonucleotide und deren Verwendung |
US5530000A (en) | 1993-12-22 | 1996-06-25 | Ortho Pharmaceutical Corporation | Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors |
GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US5597826A (en) | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
DE19502912A1 (de) | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilisierte Oligonucleotide |
US6326487B1 (en) | 1995-06-05 | 2001-12-04 | Aventis Pharma Deutschland Gmbh | 3 modified oligonucleotide derivatives |
US5827850A (en) | 1995-09-25 | 1998-10-27 | Sanofi Pharmaceuticals, Inc. | 1,2,4-benzotriazine oxides formulations |
CN100366253C (zh) | 1995-09-25 | 2008-02-06 | 赛诺菲-安万特美国有限责任公司 | 1,2,4-苯并三嗪氧化物制剂 |
JPH09274290A (ja) | 1996-02-07 | 1997-10-21 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料用の現像液および処理方法 |
DK0939632T3 (da) | 1996-02-23 | 2006-01-30 | Lilly Co Eli | Non-peptidyl vasopressin V1a antagonister |
DE59707681D1 (de) | 1996-10-28 | 2002-08-14 | Rolic Ag Zug | Vernetzbare, photoaktive Silanderivate |
EP0968284B1 (en) | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
JP3734903B2 (ja) | 1996-11-21 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
JPH10153838A (ja) | 1996-11-22 | 1998-06-09 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
JP3720931B2 (ja) | 1996-11-26 | 2005-11-30 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料の処理方法 |
US5935383A (en) | 1996-12-04 | 1999-08-10 | Kimberly-Clark Worldwide, Inc. | Method for improved wet strength paper |
JPH10207019A (ja) | 1997-01-22 | 1998-08-07 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
JPH10213820A (ja) | 1997-01-31 | 1998-08-11 | Canon Inc | 液晶素子及び液晶装置 |
DE59807348D1 (de) | 1997-02-05 | 2003-04-10 | Rolic Ag Zug | Photovernetzbare Silanderivate |
JPH10260512A (ja) | 1997-03-19 | 1998-09-29 | Fuji Photo Film Co Ltd | ハロゲン化銀感光材料の処理方法 |
US6070126A (en) | 1997-06-13 | 2000-05-30 | William J. Kokolus | Immunobiologically-active linear peptides and method of identification |
US6235736B1 (en) | 1997-06-24 | 2001-05-22 | Nikken Chemicals Co., Ltd. | 3-anilino-2-cycloalkenone derivatives |
US6635626B1 (en) | 1997-08-25 | 2003-10-21 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
US6685938B1 (en) | 1998-05-29 | 2004-02-03 | The Scripps Research Institute | Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases |
US6136971A (en) | 1998-07-17 | 2000-10-24 | Roche Colorado Corporation | Preparation of sulfonamides |
US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
WO2000025780A1 (en) | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
FR2792314B1 (fr) | 1999-04-15 | 2001-06-01 | Adir | Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DE60006541D1 (de) * | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
CA2377771A1 (en) | 1999-07-01 | 2001-01-11 | Ajinomoto Co., Inc. | Heterocyclic compounds and medical use thereof |
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
AU763976B2 (en) | 1999-07-23 | 2003-08-07 | Shionogi & Co., Ltd. | Th2 differentiation inhibitors |
US6093838A (en) | 1999-08-16 | 2000-07-25 | Allergan Sales, Inc. | Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
US6127382A (en) | 1999-08-16 | 2000-10-03 | Allergan Sales, Inc. | Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
EP1223170B1 (en) | 1999-10-12 | 2005-12-28 | Takeda Pharmaceutical Company Limited | Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof |
US6638929B2 (en) | 1999-12-29 | 2003-10-28 | Wyeth | Tricyclic protein kinase inhibitors |
US6153752A (en) | 2000-01-28 | 2000-11-28 | Creanova, Inc. | Process for preparing heterocycles |
US20020165244A1 (en) | 2000-01-31 | 2002-11-07 | Yuhong Zhou | Mucin synthesis inhibitors |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US6605615B2 (en) | 2000-03-01 | 2003-08-12 | Tularik Inc. | Hydrazones and analogs as cholesterol lowering agents |
JP2001247411A (ja) | 2000-03-09 | 2001-09-11 | Tomono Agrica Co Ltd | 有害生物防除剤 |
US6608048B2 (en) | 2000-03-28 | 2003-08-19 | Wyeth Holdings | Tricyclic protein kinase inhibitors |
KR20030009416A (ko) | 2000-04-04 | 2003-01-29 | 시오노기세이야쿠가부시키가이샤 | 고지용성 약물을 함유하는 유성 조성물 |
US6471968B1 (en) | 2000-05-12 | 2002-10-29 | Regents Of The University Of Michigan | Multifunctional nanodevice platform |
DE10024622A1 (de) | 2000-05-18 | 2001-11-22 | Piesteritz Stickstoff | N-(2-Pyrimidinyl)(thio)phosphorsäuretriamide, Verfahren zu ihrer Herstellung und deren Verwendung als Mittel zur Regulierung bzw. Hemmung der enzymatischen Harnstoff-Hydrolyse |
DE60114518T2 (de) | 2000-07-06 | 2006-08-10 | Fuji Photo Film Co. Ltd., Minamiashigara | Flüssigkristallzusammensetzung, die Flüssigkristallmoleküle und Ausrichtungsmittel enthält |
MXPA03001306A (es) | 2000-08-11 | 2003-10-15 | Boehringer Ingelheim Pharma | Compuestos heterociclicos utiles como inhibidores de las quinasas de tirosina. |
US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
JP2002221770A (ja) | 2001-01-24 | 2002-08-09 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料およびその処理方法 |
WO2002096903A2 (fr) | 2001-05-28 | 2002-12-05 | Aventis Pharma S.A. | Derives chimiques et leur application comme agent antitelomerase |
PL367130A1 (en) | 2001-05-29 | 2005-02-21 | Schering Aktiengesellschaft | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
DE60214198T2 (de) | 2001-07-03 | 2007-08-09 | Vertex Pharmaceuticals Inc., Cambridge | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
UY27487A1 (es) * | 2001-10-17 | 2003-05-30 | Boehringer Ingelheim Pharma | Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
US20060292206A1 (en) * | 2001-11-26 | 2006-12-28 | Kim Steven W | Devices and methods for treatment of vascular aneurysms |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US20030166932A1 (en) | 2002-01-04 | 2003-09-04 | Beard Richard L. | Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
JP2005524668A (ja) | 2002-03-01 | 2005-08-18 | スミスクライン ビーチャム コーポレーション | ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用 |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
WO2004005283A1 (en) | 2002-07-09 | 2004-01-15 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
ES2445208T3 (es) | 2002-07-29 | 2014-02-28 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias |
ES2294344T3 (es) | 2002-08-02 | 2008-04-01 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su utilizacion como inhibidores de c-kit. |
PL375447A1 (en) | 2002-08-14 | 2005-11-28 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
US7230101B1 (en) | 2002-08-28 | 2007-06-12 | Gpc Biotech, Inc. | Synthesis of methotrexate-containing heterodimeric molecules |
DE10240261A1 (de) | 2002-08-31 | 2004-03-11 | Clariant Gmbh | Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Halogen-Metall-Austauschreaktionen |
DE10240262A1 (de) | 2002-08-31 | 2004-03-11 | Clariant Gmbh | Verfahren zur metallorganischen Herstellung organischer Zwischenprodukte über Aryllithium-Basen |
US20050282814A1 (en) | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
US7208493B2 (en) | 2002-10-03 | 2007-04-24 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
US20060167021A1 (en) | 2002-10-04 | 2006-07-27 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Inhibition of src for treatment of reperfusion injury related to revascularization |
AU2003287178A1 (en) | 2002-10-10 | 2004-05-04 | Smithkline Beecham Corporation | Chemical compounds |
WO2004037176A2 (en) | 2002-10-21 | 2004-05-06 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
WO2004037814A1 (en) | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
DE10250708A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
NZ540138A (en) | 2002-11-19 | 2008-07-31 | Memory Pharm Corp | Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors |
JP2006510661A (ja) | 2002-12-06 | 2006-03-30 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Pi3kの阻害剤としてのベンズオキサジン−3−オン類及びその誘導体 |
JP3837670B2 (ja) | 2002-12-12 | 2006-10-25 | 富士通株式会社 | データ中継装置、連想メモリデバイス、および連想メモリデバイス利用情報検索方法 |
AU2003299600A1 (en) | 2002-12-20 | 2004-07-29 | Pharmacia Corpration | The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
JP2006518333A (ja) | 2002-12-20 | 2006-08-10 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸 |
ATE412657T1 (de) | 2002-12-24 | 2008-11-15 | Astrazeneca Ab | Therapeutische quinazolin-derivate |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
WO2004074266A1 (en) | 2003-02-07 | 2004-09-02 | Janssen Pharmaceutica N.V. | Hiv inhibiting 1,2,4-triazines |
CA2513527C (en) | 2003-02-07 | 2012-08-14 | Janssen Pharmaceutica N.V. | Pyrimidine derivatives for the prevention of hiv infection |
CA2515544A1 (en) | 2003-02-11 | 2004-08-26 | Kemia Inc. | Compounds for the treatment of viral infection |
CL2004000303A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
ES2634840T5 (es) | 2003-04-24 | 2022-12-22 | Coopervision Int Ltd | Lentes de contacto de hidrogel y sistemas de envase y procedimientos de producción de los mismos |
MY147449A (en) | 2003-08-15 | 2012-12-14 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
JP2007505858A (ja) | 2003-09-18 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | 増殖性障害の処置に有用な2,4−ジ(フェニルアミノ)ピリミジン |
DK2392564T3 (da) | 2003-09-26 | 2014-01-13 | Exelixis Inc | c-Met-modulatorer og anvendelsesfremgangsmåder |
WO2005035541A1 (en) | 2003-10-07 | 2005-04-21 | Amedis Pharmaceuticals Ltd. | Silicon compounds and their use |
DE10356579A1 (de) | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | Aminderivate |
BRPI0507373A (pt) | 2004-01-23 | 2007-07-10 | Amgen Inc | compostos e método de uso |
CA2567574C (en) * | 2004-04-08 | 2013-01-08 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
JPWO2005108370A1 (ja) | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
NZ553492A (en) | 2004-08-25 | 2010-11-26 | Targegen Inc | Triazole derivatives and methods of use |
US7210697B2 (en) | 2004-12-16 | 2007-05-01 | Tricam International, Inc. | Convertible handle |
EP1841431A4 (en) | 2005-01-26 | 2009-12-09 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
US20060247250A1 (en) | 2005-03-16 | 2006-11-02 | Targegen, Inc. | Pyrimidine inhibitors of kinases |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
EP1893216A4 (en) | 2005-06-08 | 2012-08-08 | Targegen Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
JP5321061B2 (ja) | 2005-08-11 | 2013-10-23 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 不飽和複素環誘導体 |
TW200745066A (en) | 2005-09-16 | 2007-12-16 | Torrent Pharmaceuticals Ltd | Novel PTP1B inhibitors |
US20070072682A1 (en) | 2005-09-29 | 2007-03-29 | Crawford James T Iii | Head to head electronic poker game assembly and method of operation |
PT1951684T (pt) | 2005-11-01 | 2016-10-13 | Targegen Inc | Inibidores de cinases de tipo biaril-meta-pirimidina |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US20070149508A1 (en) | 2005-11-02 | 2007-06-28 | Targegen, Inc. | Six membered heteroaromatic inhibitors targeting resistant kinase mutations |
US7691858B2 (en) | 2006-04-25 | 2010-04-06 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
WO2009026346A1 (en) | 2007-08-20 | 2009-02-26 | Targegen Inc. | Thiazolidine compounds, and methods of making and using same |
WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
WO2009055674A1 (en) | 2007-10-26 | 2009-04-30 | Targegen Inc. | Pyrrolopyrimidine alkynyl compounds and methods of making and using same |
EP2254581A1 (en) | 2008-02-08 | 2010-12-01 | TargeGen, Inc. | Pteridine derivatives for treating respiratory disease |
AU2009279825A1 (en) | 2008-08-05 | 2010-02-11 | Targegen, Inc. | Methods of treating thalassemia |
-
2005
- 2005-04-07 CA CA2567574A patent/CA2567574C/en not_active Expired - Fee Related
- 2005-04-07 NZ NZ551027A patent/NZ551027A/en not_active IP Right Cessation
- 2005-04-07 EP EP12167912A patent/EP2543376A1/en not_active Withdrawn
- 2005-04-07 AU AU2005231507A patent/AU2005231507B2/en not_active Ceased
- 2005-04-07 US US11/102,405 patent/US7456176B2/en active Active
- 2005-04-07 KR KR1020067023392A patent/KR20070011458A/ko not_active Application Discontinuation
- 2005-04-07 NZ NZ588139A patent/NZ588139A/en not_active IP Right Cessation
- 2005-04-07 RU RU2006139258/04A patent/RU2006139258A/ru not_active Application Discontinuation
- 2005-04-07 EP EP05762774.7A patent/EP1809614B1/en not_active Not-in-force
- 2005-04-07 WO PCT/US2005/012057 patent/WO2005096784A2/en active Application Filing
-
2006
- 2006-10-26 IL IL178908A patent/IL178908A/en not_active IP Right Cessation
-
2008
- 2008-01-21 HK HK08100766.4A patent/HK1110578A1/xx not_active IP Right Cessation
- 2008-09-09 US US12/207,019 patent/US20090275569A1/en not_active Abandoned
-
2010
- 2010-12-28 US US12/980,235 patent/US8481536B2/en active Active
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP1809614A4 |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2543376A1 (en) * | 2004-04-08 | 2013-01-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
US8481536B2 (en) | 2004-04-08 | 2013-07-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
US8372971B2 (en) | 2004-08-25 | 2013-02-12 | Targegen, Inc. | Heterocyclic compounds and methods of use |
EP1799656A1 (en) * | 2004-08-25 | 2007-06-27 | Targegen, Inc. | Heterocyclic compounds and methods of use |
EP1799656A4 (en) * | 2004-08-25 | 2009-09-02 | Targegen Inc | HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
AU2005276974B2 (en) * | 2004-08-25 | 2012-08-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
EP2532653A1 (en) * | 2004-08-25 | 2012-12-12 | Targegen, Inc. | Benzo[1,2,4]triazines as protein kinase modulators |
US8084618B2 (en) | 2004-08-25 | 2011-12-27 | Targegen, Inc. | Heterocyclic compounds and methods of use |
WO2006131835A3 (en) * | 2005-02-01 | 2007-05-10 | Sentinel Oncology Ltd | Heterocyclic triazines as hypoxic selective protein kinase inhibitors |
WO2006131835A2 (en) * | 2005-02-01 | 2006-12-14 | Sentinel Oncology Limited | Heterocyclic triazines as hypoxic selective protein kinase inhibitors |
US10010536B2 (en) | 2005-05-10 | 2018-07-03 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US9527816B2 (en) | 2005-05-10 | 2016-12-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
EP1893216A4 (en) * | 2005-06-08 | 2012-08-08 | Targegen Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES |
EP1893216A1 (en) * | 2005-06-08 | 2008-03-05 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
US7858782B2 (en) | 2006-12-15 | 2010-12-28 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
EP2923703A1 (en) | 2006-12-15 | 2015-09-30 | Abraxis BioScience, Inc. | Triazine derivatives and their therapeutical applications |
EP2425840A1 (en) | 2006-12-15 | 2012-03-07 | Abraxis BioScience, Inc. | Triazine derivatives and their therapeutical applications |
US8580786B2 (en) | 2006-12-15 | 2013-11-12 | Nant Holdings Ip, Llc | Triazine derivatives and their therapeutical applications |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US9290450B2 (en) | 2008-06-03 | 2016-03-22 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
USRE47142E1 (en) | 2008-06-03 | 2018-11-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US10975352B2 (en) | 2008-12-03 | 2021-04-13 | The Scripps Research Institute | Methods of enhancing cell survival of stem cells |
US9896655B2 (en) | 2008-12-03 | 2018-02-20 | The Scripps Research Institute | Methods of enhancing cell survival of stem cells |
AU2009322346B2 (en) * | 2008-12-03 | 2015-07-02 | The Scripps Research Institute | Stem cell cultures |
US10351822B2 (en) | 2008-12-03 | 2019-07-16 | The Scripps Research Institute | Methods of enhancing cell survival of stem cells |
US9340525B2 (en) | 2008-12-03 | 2016-05-17 | The Scripps Research Institute | Stem cell cultures |
WO2010076238A1 (en) | 2008-12-29 | 2010-07-08 | Fovea Pharmaceuticals Sa | Substituted quinazoline compounds |
WO2010092041A1 (en) | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals Sa | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
US8716473B2 (en) | 2009-05-26 | 2014-05-06 | Sentinel Oncology Limited | Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase |
JP2012528136A (ja) * | 2009-05-26 | 2012-11-12 | センティネル・オンコロジー・リミテッド | p70S6キナーゼの阻害剤としての置換ベンゾトリアジン類およびキノキサリン類 |
US8877924B2 (en) | 2009-06-09 | 2014-11-04 | NantBio Inc. | Benzyl substituted triazine derivatives and their therapeutical applications |
US9409903B2 (en) | 2009-06-09 | 2016-08-09 | Nantbioscience, Inc. | Benzyl substituted triazine derivatives and their therapeutical applications |
US9078902B2 (en) | 2009-06-09 | 2015-07-14 | Nantbioscience, Inc. | Triazine derivatives and their therapeutical applications |
WO2011161159A1 (en) | 2010-06-22 | 2011-12-29 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
US9675593B2 (en) | 2012-10-02 | 2017-06-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10376497B2 (en) | 2012-10-02 | 2019-08-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10898474B2 (en) | 2012-10-02 | 2021-01-26 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10544161B2 (en) | 2014-04-02 | 2020-01-28 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10246393B2 (en) | 2016-10-31 | 2019-04-02 | Tosoh Corporation | Method for producing aromatic compound |
Also Published As
Publication number | Publication date |
---|---|
CA2567574A1 (en) | 2005-10-20 |
US20090275569A1 (en) | 2009-11-05 |
EP1809614A4 (en) | 2010-02-17 |
NZ588139A (en) | 2012-02-24 |
US8481536B2 (en) | 2013-07-09 |
NZ551027A (en) | 2011-01-28 |
RU2006139258A (ru) | 2008-05-20 |
KR20070011458A (ko) | 2007-01-24 |
US20110294796A1 (en) | 2011-12-01 |
EP1809614A2 (en) | 2007-07-25 |
EP1809614B1 (en) | 2014-05-07 |
AU2005231507A1 (en) | 2005-10-20 |
HK1110578A1 (en) | 2008-07-18 |
IL178908A (en) | 2015-09-24 |
AU2005231507B2 (en) | 2012-03-01 |
WO2005096784A3 (en) | 2009-02-19 |
US20050245524A1 (en) | 2005-11-03 |
EP2543376A1 (en) | 2013-01-09 |
CA2567574C (en) | 2013-01-08 |
IL178908A0 (en) | 2011-08-01 |
US7456176B2 (en) | 2008-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005231507B2 (en) | Benzotriazine inhibitors of kinases | |
DK1951684T3 (en) | BIARYLMETAPYRIMIDIN kinase inhibitors | |
AU2003282726B2 (en) | Vasculostatic agents and methods of use thereof | |
AU2006227628A1 (en) | Pyrimidine compounds and methods of use | |
WO2007056075A2 (en) | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | |
JP6175139B2 (ja) | 新規トリアジン化合物 | |
CN111566100B (zh) | 嘧啶类化合物、其制备方法及其医药用途 | |
EP1877398B1 (en) | Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors | |
CN101426772B (zh) | 激酶的苯并三嗪抑制物 | |
AU2012202928A1 (en) | Benzotriazine inhibitors of kinases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 178908 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005231507 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 551027 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006502199 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200609267 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006139258 Country of ref document: RU Ref document number: 1020067023392 Country of ref document: KR Ref document number: 6617/DELNP/2006 Country of ref document: IN Ref document number: 2005762774 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2567574 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2005231507 Country of ref document: AU Date of ref document: 20050407 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005231507 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580018660.1 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067023392 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005762774 Country of ref document: EP |